Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus pulsed imatinib with or without lenograstim in CML patients with complete cytogenetic response
ISRCTN56578157Phase 4Completed
- Sponsor
- Blood Cancer UK
- Start
- Oct 2004
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of imatinib and lenograstim in chronic myelogenous leukemia (CML) (3 arms), sponsored by Blood Cancer UK. Primary endpoints: Safety of combination G-CSF and imatinib and Safety of pulsed imatinib arms. Started Oct 2004; status: completed.
02
Drugs
imatiniblenograstim
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ISRCTN56578157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56578157.